Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan C Buckner

Showing results (21-30 of 138) with videos related to

Pageof 14
Sort By:
Neuro-Oncology|October 15, 2014
Impact of imaging measurements on response assessment in glioblastoma clinical trialsDavid A Reardon, Karla V Ballman, Jan C Buckner, et al.
Expert Review of Anticancer Therapy|October 14, 2005
Treatment options for brain metastases from melanomaRobert R McWilliams, Ravi D Rao, Paul D Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2006
Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of responseKurt A Jaeckle, Karla V Ballman, Ravi D Rao, et al.
Neuro-Oncology|June 21, 2003
Unusual presentation of adult metastatic peritoneal medulloblastoma associated with a ventriculoperitoneal shunt: a case study and review of the literaturePaul M Magtibay, Jonathan A Friedman, Ravi D Rao, et al.
Neuro-Oncology Practice|August 7, 2019
Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendrogliomaMichael W Ruff, Jan C Buckner, Derek R Johnson, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?Martin C Tom, Daniel P Cahill, Jan C Buckner, et al.
Journal of the Neurological Sciences|September 3, 2019
Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastomaLucie Petrova, Panagiotis Korfiatis, Ondra Petr, et al.
Journal of Digital Imaging|August 9, 2017
Residual Deep Convolutional Neural Network Predicts MGMT Methylation StatusPanagiotis Korfiatis, Timothy L Kline, Daniel H Lachance, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trialsMichelle R Mahoney, Daniel J Sargent, Michael J O'Connell, et al.
International Journal of Radiation Oncology, Biology, Physics|May 23, 2002
Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomasRavi D Rao, Stephan D Thomé, Judith O'Fallon, et al.
Pageof 14

Showing results (21-30 of 138) with videos related to

Sort By:
Pageof 14
Neuro-Oncology|October 15, 2014
Impact of imaging measurements on response assessment in glioblastoma clinical trialsDavid A Reardon, Karla V Ballman, Jan C Buckner, et al.
Expert Review of Anticancer Therapy|October 14, 2005
Treatment options for brain metastases from melanomaRobert R McWilliams, Ravi D Rao, Paul D Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2006
Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of responseKurt A Jaeckle, Karla V Ballman, Ravi D Rao, et al.
Neuro-Oncology|June 21, 2003
Unusual presentation of adult metastatic peritoneal medulloblastoma associated with a ventriculoperitoneal shunt: a case study and review of the literaturePaul M Magtibay, Jonathan A Friedman, Ravi D Rao, et al.
Neuro-Oncology Practice|August 7, 2019
Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendrogliomaMichael W Ruff, Jan C Buckner, Derek R Johnson, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?Martin C Tom, Daniel P Cahill, Jan C Buckner, et al.
Journal of the Neurological Sciences|September 3, 2019
Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastomaLucie Petrova, Panagiotis Korfiatis, Ondra Petr, et al.
Journal of Digital Imaging|August 9, 2017
Residual Deep Convolutional Neural Network Predicts MGMT Methylation StatusPanagiotis Korfiatis, Timothy L Kline, Daniel H Lachance, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trialsMichelle R Mahoney, Daniel J Sargent, Michael J O'Connell, et al.
International Journal of Radiation Oncology, Biology, Physics|May 23, 2002
Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomasRavi D Rao, Stephan D Thomé, Judith O'Fallon, et al.
Pageof 14